Global Landscape of Encephalitis: Key Priorities to Reduce Future Disease Burden
- PMID: 37436770
- PMCID: PMC10686956
- DOI: 10.1093/cid/ciad417
Global Landscape of Encephalitis: Key Priorities to Reduce Future Disease Burden
Abstract
Encephalitis affects people across the lifespan, has high rates of mortality and morbidity, and results in significant neurological sequelae with long-term consequences to quality of life and wider society. The true incidence is currently unknown due to inaccurate reporting systems. The disease burden of encephalitis is unequally distributed across the globe being highest in low- and middle-income countries where resources are limited. Here countries often lack diagnostic testing, with poor access to essential treatments and neurological services, and limited surveillance and vaccination programs. Many types of encephalitis are vaccine preventable, whereas others are treatable with early diagnosis and appropriate management. In this viewpoint, we provide a narrative review of key aspects of diagnosis, surveillance, treatment, and prevention of encephalitis and highlight priorities for public health, clinical management, and research, to reduce the disease burden.
Keywords: burden; diagnosis; encephalitis; treatment; vaccination.
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. T. S. reports royalties for text and non-fiction books from Oxford University Press, Elsevier, Liverpool University Press, and Cambridge University Press; consulting fees from Medicines and Healthcare products Regulatory Agency (MHRA); a pending patent for bacterial meningitis test (no. GB1606537); participation on a Data Safety Monitoring Committee for GSK; participation on advisory boards for GSK (advisor to Ebola Vaccine Programme and Siemens Diagnostic Programme), Siemens (Healthineers Chair), WHO (Neruro-COVID Task force co-chair), UK Government (Dangerous Pathogens Committee), MHRA (Expert Working Group on COVID-19 vaccines), UK COVID-19 Therapeutics Panel, Commission on Human Medicines Committee of the Medicines and Healthcare products Regulatory Agency (COVID-19 Vaccines Benefit Risk Expert Working Group); and previously held shares of Medefer Solutions. NWSD reports participation as Chair of the external review panel for Encephlg trial (IRAS ID 280904) and Chair of the Scientific Advisory Panel for the Encephalitis Society. J. G. reports contracts with a range of clients through their consultancy business and has in the past received consultancy fees from the Encephalitis Society. A. E. is the CEO of The Encephalitis Society and reports society-received charitable grants from Pfizer, CSL Behring, Bavarian Nordic, Snofi, UC, and Valneva; royalties from an authored book; institutional payments for speaking engagements from Valneva, Pfizer, and Eurolmmun. B. D. M. reports honoraria for presentations at SCRIPPS and University of Massachusetts; payment for expert testimony for Midicolegal work; and a role as Vice Chair of the Scientific Advisory Panel for the Encephalitis Society. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
Expansion of syndromic vaccine preventable disease surveillance to include bacterial meningitis and Japanese encephalitis: evaluation of adapting polio and measles laboratory networks in Bangladesh, China and India, 2007-2008.Vaccine. 2015 Feb 25;33(9):1168-75. doi: 10.1016/j.vaccine.2015.01.004. Epub 2015 Jan 15. Vaccine. 2015. PMID: 25597940 Free PMC article.
-
The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335. JBI Database System Rev Implement Rep. 2015. PMID: 26571284
-
Childhood encephalitis in the Greater Mekong region (the SouthEast Asia Encephalitis Project): a multicentre prospective study.Lancet Glob Health. 2022 Jul;10(7):e989-e1002. doi: 10.1016/S2214-109X(22)00174-7. Lancet Glob Health. 2022. PMID: 35714649 Free PMC article.
-
Economic Burden of Chronic Ill Health and Injuries for Households in Low- and Middle-Income Countries.In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, Nugent R, editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 27. Chapter 6. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, Nugent R, editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 27. Chapter 6. PMID: 30212160 Free Books & Documents. Review.
Cited by
-
Validation of a risk score to differentiate autoimmune and viral encephalitis: a Nationwide Cohort Study in Denmark.J Neurol. 2024 Aug;271(8):4972-4981. doi: 10.1007/s00415-024-12392-3. Epub 2024 May 18. J Neurol. 2024. PMID: 38761191 Free PMC article.
-
Pediatric non-congenital central nervous system infections: role of imaging in the emergency department.Pediatr Radiol. 2025 Apr;55(4):806-823. doi: 10.1007/s00247-025-06193-7. Epub 2025 Feb 28. Pediatr Radiol. 2025. PMID: 40019500 Review.
-
The importance of long-term studies in children following viral infection of the central nervous system.EClinicalMedicine. 2025 May 26;84:103263. doi: 10.1016/j.eclinm.2025.103263. eCollection 2025 Jun. EClinicalMedicine. 2025. PMID: 40503513 Free PMC article. Review.
-
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.Lancet Reg Health Southeast Asia. 2025 Jan 3;33:100527. doi: 10.1016/j.lansea.2024.100527. eCollection 2025 Feb. Lancet Reg Health Southeast Asia. 2025. PMID: 39866590 Free PMC article. Review.
-
Development and internal validation of clinical prediction models for scrub typhus and doxycycline-treatable causes in paediatric acute encephalitis syndrome in Karnataka, India: a multicentre, prospective study.Lancet Reg Health Southeast Asia. 2025 Jun 26;39:100626. doi: 10.1016/j.lansea.2025.100626. eCollection 2025 Aug. Lancet Reg Health Southeast Asia. 2025. PMID: 40672782 Free PMC article.
References
-
- Khandaker G, Jung J, Britton PN, King C, Yin JK, Jones CA. Long-term outcomes of infective encephalitis in children: a systematic review and meta-analysis. Dev Med Child Neurol 2016; 58:1108–15. - PubMed
-
- The Encephalitis Society . Encephalitis in adults: a guide. 2008.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical